

# Pregnancy in women with liver cirrhosis is associated with increased risk for complications: a systematic review and meta-analysis of the literature

Laurine van der Slink<sup>1</sup>, Irma Scholten<sup>2</sup>, Faridi van Etten-Jamaludin<sup>1</sup>, Bart Takkenberg<sup>1</sup>, and Rebecca Painter<sup>1</sup>

<sup>1</sup>Amsterdam UMC Locatie Meibergdreef

<sup>2</sup>Deventer Hospital

March 19, 2021

## Abstract

**Background** Pregnancy and liver cirrhosis is a rare but increasing combination. Liver cirrhosis can raise the chance of maternal and fetal mortality and morbidity, although the exact risks remain unclear. **Objective** To provide a systematic literature review and meta-analysis on maternal, fetal and obstetric complications among pregnant women with liver cirrhosis. **Search strategy** We performed a systematic literature search in the databases PubMed/MEDLINE and EMBASE (Ovid) from inception through 25 January 2021. **Selection criteria** Studies including pregnancies with liver cirrhosis and controls were eligible. **Data collection and analysis** Two reviewers independently evaluated study eligibility. We used the random-effects model for meta-analysis. **Main results** Our search yielded 3118 unique papers. We included 11 studies, including 2912 pregnancies in women with cirrhosis from 1982-2020. Seven studies were eligible for inclusion in the meta-analysis. The overall maternal mortality rate was 0.89%. Maternal mortality and variceal hemorrhage decreased comparing recent and older studies. Most cases of maternal mortality due to variceal hemorrhage (70%) occurred during vaginal delivery. Pregnant women with liver cirrhosis had a higher chance of preterm delivery (OR 6.7 95% CI 5.1- 9.1), cesarean section (OR 2.6, 95% CI 1.7-3.9), preeclampsia (OR 3.8, 95% CI 2.2-6.5) and small for gestational age neonates (OR 2.6, 95% CI 1.6-4.2) compared to the general obstetric population. Subgroup-analyses could not be conducted. **Conclusions** Liver cirrhosis in pregnant women is associated with serious increases in maternal mortality and obstetric and fetal complications. Large international prospective studies are needed to identify risk factors for unfavorable outcome.

## Introduction

Pregnancy is a rare event in women with liver cirrhosis in part due to decreased natural fertility rates.<sup>1,2</sup> The prevalence of cirrhosis in women of reproductive age is 0.045%.<sup>3</sup> The incidence of cirrhosis in pregnancy is reported as approximately 1 per 4500 pregnancies.<sup>4, 5</sup> Worldwide, the most common causes of liver cirrhosis in women are viral hepatitis, autoimmune hepatitis, alcoholic liver disease and non-alcohol related fatty liver disease.<sup>1</sup> Although pregnancy and cirrhosis is a rare combination, it appears to have become more frequent in the last decades possibly owing to improvements in the treatment of liver cirrhosis, increased awareness of cirrhosis after the introduction of screening in high risk populations, and the availability of assisted reproductive techniques.<sup>6-8</sup> For clinicians and patients alike, when deciding on family planning and obstetric management, the effects of liver cirrhosis on the course of pregnancy and the effects of pregnancy on underlying cirrhosis are both of importance.

Previous studies have shown that pregnancy in women with cirrhosis is associated with a high risk of complications, including maternal and perinatal mortality.<sup>3,9</sup> However, studies are small and report on a variety of outcomes.<sup>5, 10-14</sup> This makes it difficult to advise both patients with liver cirrhosis and their

clinicians on the course of a planned pregnancy. A systematic review and meta-analysis of the literature could provide with robust estimates of the risks involved in pregnancy. Here, we provide a systematic review reporting on the maternal, fetal and obstetric complications among pregnant women with liver cirrhosis.

## Methods

The protocol of this review was registered in PROSPERO (CRD42018080575) on 1 December 2017. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement and the Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. None of the authors received specific funding for this review. There was no patient or public involvement in the development or implementation of this review.

### Search strategy

A literature search was performed in the databases PubMed/MEDLINE and EMBASE (Ovid) from inception to 25 January 2021. The search had no language restrictions. We used medical subject headings as well as title and abstract terms and word variants of pregnancy and liver cirrhosis. Appendix S1 presents the complete search strategy.

### Study selection process

We selected cohort studies and case control studies with patients who had liver cirrhosis and were pregnant. Diagnoses of liver cirrhosis were considered confirmed when based on biopsy findings or based on imaging combined with laboratory findings. Cohorts or case control studies had to include a minimum series of five patients with liver cirrhosis. Results had to contain at least one item of one of the designated outcome domains (see heading ‘outcome measurements’). We included studies in the meta-analysis if they contained a control group. When our search found papers which analyzed identical patient populations multiple times, and which reported on identical outcomes, we selected the most recent or most relevant study, and excluded the other studies reporting on the same population. Other exclusion criteria were non-human studies, studies outside pregnancy and case reports, case series, opinions or reviews.

Two reviewers (LLS and RBT) independently screened the titles and abstracts of studies retrieved by the database searches. We requested the full text if a study was potentially relevant and performed independent screening to assess eligibility in duplo on full text. Disagreement about including a study were resolved through discussion or by consulting a third reviewer (RCP).

### Quality assessment

We used the Newcastle-Ottawa scale for cohort studies for quality assessment and estimating the risk of bias. Two reviewers (LLS and IS) independently assessed the included studies. We did not exclude studies based on poor quality.

### Outcome measurements

The outcomes of interest were divided into three domains, maternal complications, obstetric complications and fetal outcome or complications. Maternal complications included maternal mortality, hepatic decompensation, gastrointestinal bleeding or variceal bleeding. We defined maternal mortality as maternal death during pregnancy or within 42 days of termination of pregnancy.<sup>15</sup> We defined hepatic decompensation as the presence of jaundice, ascites or hepatic encephalopathy.

Obstetric complications included caesarean delivery, preterm delivery (birth <37 completed weeks gestation), postpartum hemorrhage (loss of >500 ml blood within 24 hours during or after delivery), miscarriage (pregnancy loss before 20th week), placental abruption and hypertensive disorders of pregnancy (including pregnancy induced hypertension (PIH; systolic blood pressure [?]90 mmHg or diastolic blood pressure [?]140 mmHg), preeclampsia (hypertension with proteinuria >300 mg per 24 hours) and the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP; diagnosed by laboratory abnormalities)).

Fetal complications included neonatal mortality (death within 28 days after pregnancy), admission at neonatal intensive care unit, intrauterine fetal demise (pregnancy loss at or after 20th week of gestation), congenital malformations and small for gestational age (SGA, birth weight less than 10th percentile for gestational age). Low birth weight (birth weight <2500 g) was used when SGA was not reported.

### Data extraction

Two authors (LLS and IS) independently extracted data from the included studies using a predefined and structured data extraction form created for this systematic review. In addition to the outcomes of interest, we extracted the study characteristics (authors, year and journal of publication), study design, inclusion and exclusion criteria, number of patients and number of pregnancies with cirrhosis and if appropriate number of controls of all included studies. In case of studies missing data, we contacted first authors, at least two times, in attempt to request these data.

### Data analysis

We performed a meta-analysis, using a random effects model, if at least three studies reported on the outcome of interest. Odds ratios (OR) and 95% confident intervals (CI) comparing women with liver cirrhosis to controls were calculated. A p-value <0.05 was considered statistically significant. We used the  $I^2$  for testing statistical heterogeneity.<sup>16</sup> Sensitivity analyses were performed when the  $I^2$  test showed evidence of high heterogeneity, corresponding to  $I^2 > 75\%$ . We performed sensitivity analyses by removing contributing papers from the analysis that were thought to be responsible for heterogeneity based on deviating study design, case definition, study population and etiology of liver cirrhosis. We used The Cochrane Manager Reviewer (REVMAN 5)<sup>17</sup> for the statistical analysis.

To analyze decreases of maternal mortality and variceal hemorrhage we calculated the odds ratio of the total events that occurred, after dichotomizing the odds ratios from studies conducted before and after the median of total study period of all included studies. Also, we made time sequenced plots to visualize the decreases of maternal mortality and variceal hemorrhage. We used the median date of inclusion of individual studies as the value on the X-axis and the incidence rates as value on the Y-axis.

### Results

Our search retrieved 3118 unique publications. After title and abstract screening, 130 studies were selected for full text eligibility screening. We included 11 studies (with 2901 pregnancies with liver cirrhosis) in the systematic review, of which 7 were eligible for the meta-analysis (Figure 1). The total number of pregnancies with liver cirrhosis included in the meta-analysis was 2685 as well as 4,283,173 pregnancies without liver cirrhosis (control group). Table 1 describes the general characteristics of included studies. All retrieved studies were cohort studies. The etiologies of liver cirrhosis in the included studies corresponded with the most common etiologies of liver cirrhosis in women worldwide.

### Quality assessment

Six studies were assessed as good quality, four studies as fair quality and one study as poor quality (Table S1). With one exception<sup>22</sup>, all studies scored at least two out of four stars for selection criteria and two out of three stars for outcome criteria. Most frequent source of risk of bias included ‘no control group’ (four studies did not include a control group), ‘selection of controls’ and ‘adequacy of follow up’, since nine studies were retrospective cohorts.

### Maternal complications

We present only descriptive data on maternal complications since we could not conduct a meta-analysis for maternal complications, due to a lack of odds ratios in the published reports on this topic. Maternal death rate was reported by eight studies and ranged from 0 to 7.8%. In total, 25 events of maternal deaths in 2794 pregnancies of women with cirrhosis (0.89%) were recorded, compared to 0,010% in control pregnancies, which is an 80-fold increase in risk (OR 80.2 95% CI 27.3 - 235.1;  $p < 0.0001$ ) The total numbers of maternal deaths in recent studies (range 1982-2002) were lower than in older studies (range 2004-2016) (OR 2.9 95%

CI 1.2-7.1;  $p = 0.02$ ). This trend in decreasing maternal mortality over time is illustrated by the time sequenced plots of the incidences of included studies (Figure S2). The most common cause of maternal death was variceal hemorrhage ( $n=13$ ), the majority of which occurred during vaginal delivery ( $n=9$ ) and some occurred during pregnancy ( $n=2$ ), during cesarean section ( $n=1$ ) or in the postpartum period ( $n=1$ ). Other causes of maternal mortality were sepsis ( $n=2$ ), preeclampsia ( $n=1$ ), hepatic decompensation ( $n=2$ ), flare of autoimmune hepatitis ( $n=1$ ) and unknown ( $n=6$ ) (figure S3).

Variceal hemorrhage, either resulting in maternal death or not, occurred 113 times in 2858 pregnancies (4,0%) reported in ten studies. In most cases the occurrence of variceal hemorrhage during pregnancy was new and had not occurred preconceptionally. The rate of preconceptional esophageal varices was mentioned in none of the included studies. In total 12% of variceal hemorrhage ended in maternal death ( $n=13$ ). The total numbers of variceal hemorrhage in recent studies (range 1982-2002) were lower than in older studies (range 2004-2016) (OR 2.7 95% CI 1.7-4.1;  $p < 0.0001$ ), as is illustrated in the time sequenced plot of incidences of variceal hemorrhage (figure S4). In the study of Rasheed et al. 47% of pregnancies were complicated by variceal hemorrhage. The remaining seven studies found lower percentages of variceal hemorrhage varying between 0 and 16%. Screening endoscopy for esophageal varices during pregnancy was reported in five recent studies with rates of 3, 17, 28, 35 and 60%. Accompanying endoscopic therapy for (non-bleeding) esophageal varices was reported in three studies with rates 5, 23 and 28%.

The incidence of decompensated liver cirrhosis varied between 2 and 21%, with an outlying incidence in the study of Rasheed et al., who reported 64%. Ascites prevalence was reported in five studies and ranged from 3 to 11%. Hepatic encephalopathy was also reported in five studies and ranged from 1 to 13%.

### Meta-analysis on obstetric and fetal outcomes

Meta-analysis showed a significantly higher chance on preterm delivery (OR 6.7 95% CI 5.1- 9.1), cesarean section (OR 2.6, 95% CI 1.7-3.9), preeclampsia (OR 3.8, 95% CI 2.2-6.5) and small for gestational age neonates (OR 2.6, 95% CI 1.6-4.2) in pregnant women with liver cirrhosis compared to pregnant women without liver cirrhosis (Figure 2). There was high heterogeneity in the analyses of preterm delivery, cesarean section and small for gestational age. The studies thought to be responsible for most heterogeneity were the studies of Rasheed et al. and Flemming et al., based on their study design, patient characteristics and inclusion criteria (see discussion). Sensitivity analyses after elimination of these two studies did lower the  $I^2$  on the outcomes preterm delivery ( $I^2$  before 94%, after 23%) and small for gestational ( $I^2$  before 71%, after 0%). The sensitivity analysis of cesarean section maintained moderate heterogeneity ( $I^2$  before 95%, after 68%).

### Obstetric and fetal complications

Table 2 shows the most frequently reported obstetric and fetal complications. Placental abruption was reported in three studies, respectively Flemming et al., Murthy et al. and Rasheed et al. The incidence of placental abruption was reported to be respectively 1, 6 and 10% in these studies. The incidence of congenital malformations was reported in the study of Hagström et al. and Salman et al. to be respectively 2 and 3%.

## Discussion

### Main results

Our study demonstrates that women with liver cirrhosis have increased risks on maternal, fetal and obstetric complications during pregnancy and delivery compared to healthy pregnant women. The maternal mortality rate, although lower in recent studies, remained high at 0.89%, where in the general obstetric population maternal mortality is exceedingly rare at 0.010%. Variceal hemorrhage occurred in 4.0% of pregnancies and remained the most common cause of maternal death among women with liver cirrhosis.

### Strengths and limitations

To the best of our knowledge, this is the first systematic review and meta-analysis on this topic. Previous reviews of the literature studied considerably fewer pregnancies, were not available in English or were no systematic reviews<sup>28-32</sup>. To ensure high quality of evidence and representativeness of the pregnant population with liver cirrhosis, we excluded case reports and case series.

Although in individual studies the quality of selection of cohorts and controls was generally high, selection bias in our study could exist, since included studies used different inclusion criteria. For example, some studies<sup>18, 24</sup> excluded decompensated cirrhosis, leading to an underestimation of reported outcomes.

Before sensitivity analysis the meta-analysis showed significant heterogeneity between studies (reasons are mentioned below). The high heterogeneity of the analysis of cesarean section ( $I^2 68\%$ ) cannot be only attributed to differences in known patient characteristics, as is demonstrated by the inability of our sensitivity analyses to lower heterogeneity to an acceptable level. Overall differences in clinical management differences in cesarean section rates between countries are more likely to underlie the heterogeneity. Specifically there may be distinct regional differences in the management of delivery in liver cirrhosis, where some local policies may favour cesarean section to prevent variceal hemorrhage during delivery, while other policies may favor vaginal delivery in order to avoid perioperative risks involved in abdominal surgery.<sup>3, 33</sup>

In our meta-analysis it was not possible to perform subgroup-analyses based on diagnosis underlying cirrhosis or severity of cirrhosis, due to the small number of events and missing information in included studies, which could in future studies further allow individualized counseling and management.

## Interpretation

The maternal mortality rate in women with liver cirrhosis was 0.89% which was an 80-fold increased risk compared to pregnant controls without cirrhosis. The most common cause of maternal mortality was variceal hemorrhage during vaginal delivery, although there were large differences in the reported rates of incidence of variceal hemorrhage.<sup>34</sup> The risk of maternal death as result of variceal bleeding may have been overestimated in our review given the decreases of maternal mortality and variceal hemorrhage in recent studies. The decrease of variceal hemorrhage is probably the result of the inclusion in (inter)national clinical guidelines to screen pregnant women with liver cirrhosis in the second trimester for early detection of esophageal varices.<sup>35</sup> In addition, the availability of treatment options like endoscopic variceal band ligation have become widely available during the past decades, which were already used in more recent studies included in this systematic review.<sup>4, 18, 20</sup> This treatment is considered safe in pregnancy<sup>36, 37</sup> and lowering the risk of (recurrent) variceal hemorrhage and resulting in lower maternal morbidity and mortality.

The risk of mortality in both pregnant and non-pregnant patients with cirrhosis depends on etiology, severity and presence of complications, as well as the presence of comorbid conditions.<sup>38</sup> The reported overall 30-day mortality rate after an episode of variceal bleeding is 15-20%<sup>8</sup>, which is similar with the mortality of 12% after a variceal bleed in pregnant women in our study. The one year mortality of non-pregnant patients with compensated liver cirrhosis is 1.0% and that of patients with compensated liver cirrhosis as well as oesophageal varices 3.4%. These data apply to all cirrhosis patients, but 67% of patients with liver cirrhosis are males older than 50 years.<sup>39</sup> In comparison the maternal mortality rates (<1%) among pregnant cirrhosis patients may be slightly lower, likely owing to the comparatively young age of pregnant women. Due to our study design, we were not able to investigate whether pregnancy is associated with more rapid progression of cirrhosis than can be expected according to age.

The meta-analysis showed significant heterogeneity, mostly attributed to two studies (Flemming et al. and Rasheed et al.) as demonstrated by our sensitivity analysis. The study of Rasheed et al. differs in various aspects from the other included studies. It is, in contrast to most other included studies, a prospective cohort study of patients from a middle-income country, possibly reflecting a lower level of care. This study included all pregnancies including miscarriages, whereas the other studies only described deliveries. Moreover, the etiology of liver cirrhosis, in this study solely viral hepatitis, differs from those in the other studies which included various causes. The study of Flemming et al. did not have major differences on study design, study population or etiology of liver cirrhosis. However, their case definition differed because their analysis

evaluated only primiparous women.

## **Conclusion**

This is the first systematic review and meta-analysis of pregnancy in women with liver cirrhosis. Liver cirrhosis complicates pregnancies for both mother and child.

## **Implications for research**

While our systematic review was able to quantify the increased risks of liver cirrhosis in pregnancy, we were insufficiently powered to demonstrate whether emerging management options have lowered some, or all of these risks. Our study was not able to provide evidence on the patient selection most likely to benefit from such management options. In particular more data regarding course and treatment of liver cirrhosis during pregnancy and treatment of specific complications (e.g. variceal hemorrhage, ascites, jaundice, hepatic encephalopathy) are needed to improve the knowledge and management of women with these health issues and identify the women more at risk than others. We suggest large prospective international studies could provide evidence for many of these knowledge gaps, and could investigate which diagnostic and treatment entities contribute to improved perinatal outcomes over time.

## **Implications for practice**

This systematic review provides evidence-based expectations for clinicians and pregnant women with cirrhosis and will improve pregnancy management for pregnant women with liver cirrhosis.

## **Disclosure of interest**

None declared. Completed disclosure of interest forms are available to view online as supporting information.

## **Contributing to authorship**

The study was conceived by RCP and RBT. FSE performed the literature search. LLS and RBT carried out selection of eligible studies. LLS and IS extracted data and carried out the data analysis. RCP supervised the data analysis. Differences of opinion were resolved by consensus with RCP. All authors were involved in interpretation of the data and revised the article critically.

## **Details of ethics approval**

None.

**Funding** None.

## **Acknowledgments**

None.

## **References**

1. Giard JM, Terrault NA. Women with Cirrhosis: Prevalence, Natural History, and Management. *Gastroenterology clinics of North America*. 2016;45(2):345-58.
2. Joshi D, James A, Quaglia A, Westbrook RH, Heneghan MA. Liver disease in pregnancy. *Lancet*. 2010;375(9714):594-605.
3. Tan J, Surti B, Saab S. Pregnancy and cirrhosis. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2008;14(8):1081-91.
4. Palatnik A, Rinella ME. Medical and Obstetric Complications Among Pregnant Women With Liver Cirrhosis. *Obstetrics and gynecology*. 2017;129(6):1118-23.

5. Aggarwal N, Sawhney H, Suril V, Vasishta K, Jha M, Dhiman RK. Pregnancy and cirrhosis of the liver. *The Australian & New Zealand journal of obstetrics & gynaecology*. 2000;39(4):503-6.
6. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. *Lancet*. 2014;383(9930):1749-61.
7. Esposti SD. Pregnancy in patients with advanced chronic liver disease. *Clin Liver Dis (Hoboken)*. 2014;4(3):62-8.
8. Sauerbruch T, Wong F. Treatment of Oesophageal Varices in Liver Cirrhosis. *Digestion*. 2019;99(4):261-6.
9. Allen AM, Hay JE. Review article: the management of cirrhosis in women. *Alimentary pharmacology & therapeutics*. 2014;40(10):1146-54.
10. Pajor A, Lehoczy D. Pregnancy in liver cirrhosis. Assessment of maternal and fetal risks in eleven patients and review of the management. *Gynecologic and obstetric investigation*. 1994;38(1):45-50.
11. Borhanmanesh F, Haghghi P. Pregnancy in patients with cirrhosis of the liver. *Obstetrics and gynecology*. 1970;36(2):315-24.
12. Whelton MJ, Sherlock S. Pregnancy in patients with hepatic cirrhosis. Management and outcome. *Lancet*. 1968;2(7576):995-9.
13. Restaino A, Campobasso C, D'Aloia A, Abbruzzese AD, Valerio A, Pansini F. Cirrhosis and pregnancy. A case report and review of the literature. *Clinical and experimental obstetrics & gynecology*. 1996;23(4):240-7.
14. Cheng YS. Pregnancy in liver cirrhosis and/or portal hypertension. *American journal of obstetrics and gynecology*. 1977;128(7):812-22.
15. Organization. WH. International Statistical Classification of Diseases and Related Health Problems, 10th Revision 2019 [ICD-10 Online Versions.: [Available from: <https://icd.who.int/browse10/2019/en>].
16. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Statistics in medicine*. 2002;21(11):1539-58.
17. Center TNC. Review Manager RevMan (5th edition). The Cochrane Collaboration 2014.
18. Salman AA, Kasem MF, Kholaf KM, Ramadan M, Yousef M, Shaaban HED, et al. Outcomes of pregnancy in Child A liver cirrhotic patients: A retrospective multicenter study. *Advances in Digestive Medicine*. 2020.
19. Flemming JA, Mullin M, Lu J, Sarkar MA, Djerboua M, Velez MP, et al. Outcomes of Pregnant Women With Cirrhosis and Their Infants in a Population-Based Study. *Gastroenterology*. 2020;159:1752-62.e10.
20. Hagstrom H, Hojjer J, Marschall HU, Williamson C, Heneghan MA, Westbrook RH, et al. Outcomes of Pregnancy in Mothers With Cirrhosis: A National Population-Based Cohort Study of 1.3 Million Pregnancies. *Hepatology*. 2018;67(11):1299-305.
21. Jena P, Sheela CN, Venkatachala RP, Devarbhavi H. Obstetric Outcome in Women with Chronic Liver Disease. *J Obstet Gynaecol India*. 2017;67(4):263-9.
22. Danielsson Borssen A, Wallerstedt S, Nyhlin N, Bergquist A, Lindgren S, Almer S, et al. Pregnancy and childbirth in women with autoimmune hepatitis is safe, even in compensated cirrhosis. *Scandinavian journal of gastroenterology*. 2015;51(4):479-85.
23. Puljic A, Caughey A, Niu B, Ameel B, Griffin E, Doss A, et al. Outcomes of pregnancies complicated by portal hypertension and esophageal varices. *American journal of obstetrics and gynecology*. 2014;1):S191-S2.
24. Rasheed SM, Abdel Monem AM, Abd Ellah AH, Abdel Fattah MS. Prognosis and determinants of pregnancy outcome among patients with post-hepatitis liver cirrhosis. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*. 2013;121(3):247-51.

25. Westbrook RH, Yeoman AD, O’Grady JG, Harrison PM, Devlin J, Heneghan MA. Model for end-stage liver disease score predicts outcome in cirrhotic patients during pregnancy. *Clin Gastroenterol Hepatol*. 2011;9(8):694-9.

26. Murthy SK, Heathcote EJ, Nguyen GC. Impact of cirrhosis and liver transplant on maternal health during labor and delivery. *Clin Gastroenterol Hepatol*. 2009;7(12):1367-72, 72 e1.

27. Britton RC. Pregnancy and esophageal varices. *American journal of surgery*. 1982;143(4):421-5.

28. Villegas Castrejon H, Karchmer S, Mravko E, Shor Pinsky V. [Post-necrotic liver cirrhosis and pregnancy. Presentation of a case and review of the literature]. *Ginecologia y obstetricia de Mexico*. 1984;52(331):271-9.

29. Bacci G, Bianchi FB, Ferramosca B, Nigro F. [Hepatic cirrhosis and pregnancy. Description of a case and review of the literature]. *Archivio di patologia e clinica medica*. 1969;45(3):245-60.

30. Moore RM, Hughes PK. Cirrhosis of the liver in pregnancy: a review of the literature and report of three cases. *Obstetrics and gynecology*. 1960;15:753-6.

31. Berenguer J, Pertejo V, Sarrion JV, Rayon M, Rodrigo M, Bagueña J. [Cirrhosis and pregnancy (report of 4 cases and review of the literature)]. *Revista clinica espanola*. 1974;135(3):275-83.

32. Rahim MN, Pirani T, Williamson C, Heneghan MA. Management of pregnancy in women with cirrhosis. *United European Gastroenterol J*. 2020:2050640620977034.

33. Hay JE. Liver disease in pregnancy. *Hepatology*. 2008;47(3):1067-76.

34. Rasheed S, Hasan I, Arafa O. Outcome of pregnancy in patients with liver cirrhosis. *International Journal of Gynecology and Obstetrics*. 2009;2):S317.

35. Tran TT, Ahn J, Reau NS. ACG Clinical Guideline: Liver Disease and Pregnancy. *The American journal of gastroenterology*. 2016;111(2):176-94; quiz 96.

36. Kamani L, Achakzai MS, Ismail FW, Kayani F. Safety of Endoscopy and Its Outcome in Pregnancy. *Cureus*. 2019;11(12):e6301.

37. Starkel P, Horsmans Y, Geubel A. Endoscopic band ligation: a safe technique to control bleeding esophageal varices in pregnancy. *Gastrointest Endosc*. 1998;48(2):212-4.

38. Villa E, Vukotic R, Camma C, Petta S, Di Leo A, Gitto S, et al. Reproductive status is associated with the severity of fibrosis in women with hepatitis C. *PloS one*. 2012;7(9):e44624.

39. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. *Journal of hepatology*. 2006;44(1):217-31.

**Table 1.** Characteristics of included studies

First author	Year of publication	Place	Study design and origin of data
Salman <sup>18</sup>	2020	Cairo, Egypt	Prospective cohort; Cairo University hospitals
Flemming <sup>19</sup>	2020	Kingston, Canada	Retrospective cohort; Multiple databases housed in the Insti
Hagström <sup>20</sup>	2018	Stockholm, Sweden	Prospective cohort; Swedish Medical Birth Register
Jena <sup>21</sup>	2017	Bangalore, India	Retrospective cohort; St. John Medical College
Palatnik <sup>4</sup>	2017	Milwaukee, USA	Retrospective cohort; Medical College of Winsconsin
Borssén <sup>22</sup>	2016	Umeå, Sweden	Retrospective cohort; questionnaire
Puljic <sup>23</sup>	2015	San Diego, USA	Retrospective cohort; databases of California Department of
Rasheed <sup>24</sup>	2013	Sohag, Egypt	Prospective cohort; Sohag University Hospital
Westbrook <sup>25</sup>	2011	London, UK	Prospective cohort; King’s College Hospital
Murthy <sup>26</sup>	2009	Toronto, Canada	Retrospective cohort; Nationwide Impatient Sample databas
Britton <sup>27</sup>	1982	Portland, USA	Retrospective cohort; Maine Medical Center

**Table 2.** fetal and obstetric complications

Study	% Cesarean section	% Preterm delivery	% Postpartum hemorrhage	% Preeclampsia
Salman et al. 2020	35.0	25.0		6.0
Flemming et al. 2020	32.7	11.4	7.0	
Hagström et al. 2018	35.9	18.6		3.9
Jena et al. 2017		17.9	17.9	17.9
Palatnik et al. 2017	25.8	45.2	6.5	19.4
Borssén et al. 2016	25.6	23.3		
Puljic et al. 2015	69.5	56.8	5.4	13.5
Rasheed et al. 2013	81.4	26.4	16.3	12.4
Westbrook et al. 2011		63.9		
Murthy et al. 2009	50.4	38.0		
Britton et al. 1982	13.3			

\*NICU = neonatal intensive care unit

**Hosted file**

Figure 1. Flow chart of study selection.pdf available at <https://authorea.com/users/402592/articles/514405-pregnancy-in-women-with-liver-cirrhosis-is-associated-with-increased-risk-for-complications-a-systematic-review-and-meta-analysis-of-the-literature>

